Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab with or without sub-Tenon triamcinolone for exudative age-related macular degeneration
ACTRN12611000091909Phase 2Recruiting
- Sponsor
- Royal Adelaide Hospital
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in exudative macular degeneration comparing Ranibizumab + sub-Tenon triamcinolone with Ranibizumab + sham sub-Tenon saline (2 arms). Primary endpoints: Visual acuity at 12 months and Number of intravitreal injections required. Started Apr 2010; status: recruiting.
02
Drugs
ranibizumabtriamcinolone acetonide
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ACTRN12611000091909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000091909.